Cynomolgus Monkey PBMCs- Rhesus Monkey PBMCs
- Cynomolgus Monkey Cerebrospinal Fluid (CSF)
- Non-Human Primate (NHP) Plasma Products
- Non-Human Primate (NHP) Serum Products
- NHP Hepatocyte, Stellate Cell, Kupffer Cell Products
- Immortalized Epithelial Cells
- Immortalized NHP Endothelial Cells
- Immortalized NHP Fibroblasts
- Immortalized Smooth Muscle Cells
- Immortalized GFP-Expressing Cells
- GFP Expressing Cells
- RFP Expressing Cells
- Luciferase Expressing Cells
- Cre Expressing Cells
- Cas9 Expressing Cells
NHP Based Gene Therapeutics Development Service
Services Published Data FAQ Customer Review Related Services and Products
Services
The rapid development of gene therapy is leading to a novel solution for disease treatment. Based on extensive non-human primate (NHP) resources, Creative Biolabs is capable of providing comprehensive and high-customized gene therapeutics development services for our global clients. Our expertise in primates has been verified by past research and development experience and will further expedite your projects.
What We Can Provide
As a dedicated NHP biospecimen and service provider, Creative Biolabs provides comprehensive NHP-based gene therapy service that covers various research fields, such as neurosciences, rare diseases, immunology and autoimmune diseases, oculopathy, cardiovascular disease, and so forth. Whether the candidate you'd like to test is viral or non-viral-based, we can prepare corresponding solutions to meet your specific needs.
Available Primate Species
Equipped with a large NHP colony, Creative Biolabs has the capability to support gene therapy research in various monkey species. We have accumulated rich experience in the selection of monkey types and will reduce unnecessary time consumption for your project. With years of experience, our professional team will ensure your project is a success.
Optional Delivery Routes
We are capable of the operation of extensive gene therapy administration routes including intrahepatic, intrathecal, intraocular, intravenous, intravenous, intratracheal, intramuscular, intranasal, intraperitoneal, intracerebroventricular and intravitreal. Additionally, our team has the strength to evaluate the feasibility of these delivery routes, which will make your gene therapy easier to obtain success.
Why Partner with Creative Biolabs
At Creative Biolabs, we treat every customer sincerely. To become your worst-worthy partner, we have made adequate preparations to provide highly competitive services with efficiency and quality.
Published Data
The study's data suggest that while AAV-mediated gene therapy is effective in elevating hFVIII levels, the immune response remains a significant challenge. The development of anti-hFVIII antibodies in nearly all animals underscores the need for strategies to
manage or mitigate immune reactions in gene therapy applications.
Figure 1 hFVIII expression and anti-hFVIII antibody generation in individual cynomolgus macaques following administration of AAVrh10.E03.TTR.hFVIIIco-SQ.PA75. Five male rhesus macaques were administered IV with 1.2x1013 GC/kg of AAVrh10.E03.TTR.hFVIIIco-SQ.PA75. Macaques were bled biweekly to evaluate hFVIII expression in plasma by ELISA. Values are expressed as mean ± SEM (solid line). Anti-hFVIII IgG titers were also evaluated biweekly in plasma by ELISA (1/dilution, dashed line). The shaded area indicates the application of the immunosuppression protocol as required.
Notably, the differential response to AAV capsids, particularly the lower immunogenicity of AAVhu37, highlights the importance of capsid selection in clinical applications. The relatively higher efficacy and lower immune response associated with AAVhu37 capsid suggest its
superiority for clinical use in hemophilia A gene therapy.
Figure 2. hFVIII expression and anti-hFVIII antibody generation in individual cynomolgus macaques following administration of AAVhu37.E03.TTR.hFVIIIco-SQ.PA75. Five male rhesus macaques were administered IV with 1.2x1013 GC/kg of AAVhu37.E03.TTR.hFVIIIco-SQ.PA75. Macaques were bled biweekly to evaluate hFVIII expression in plasma by ELISA. Values are expressed as mean ± SEM (solid line). AntihFVIII IgG titers were also evaluated biweekly in plasma by ELISA (1/dilution, dashed line). The shaded area indicates the application of the immunosuppression protocol as required.
Reference:J. A. Greig., et al. " Optimized Adeno-Associated Virus-Mediated Human Factor VIII Gene Therapy in Cynomolgus Macaques." Huaman Gene Therapy (2008).
FAQ
-
Why are non-human primates (NHPs) important in the development of gene therapies, especially for diseases like Parkinson's and autoimmune diseases?
NHPs play a crucial role in gene therapy development due to their close genetic and physiological similarities to humans. This is particularly relevant in areas like Parkinson's disease and autoimmune diseases, where the unique aspects of NHP physiology can provide more accurate insights into human responses. -
What are the safety considerations and potential risks associated with using AAV-based gene therapies in NHPs?
Understanding the safety and long-term effects of AAV-based gene therapies is critical. Studies have shown that these therapies are generally safe in NHPs, with low rates of integration into the genome and minimal risk for cancer mutations. However, ongoing research is essential to fully understand the implications of these therapies. -
How does CRISPR/Cas9 genome editing in NHP models impact gene therapy research, particularly in the context of complex diseases like HIV?
CRISPR/Cas9 genome editing in NHPs offers a powerful tool for creating more precise models of complex diseases like HIV. However, there are concerns regarding unintended on-target editing effects, such as large-scale deletions, which highlight the need for meticulous research and safety evaluations in these models.
Customer Reviews
-
Dr. Sarah Thompson, Director of Research
We approached Creative Biolabs for their NHP Gene Therapeutics Development service to assist in our groundbreaking gene therapy research. Their expertise in non-human primate models provided invaluable insights that were pivotal for our project's success. The team's comprehensive approach, from gene delivery system optimization to in vivo gene expression analysis, was impressively thorough. We were particularly impressed with their ethical standards and commitment to animal welfare, which aligns with our organization's core values. Creative Biolabs' professionalism and scientific acumen greatly accelerated our research timeline and enhanced the quality of our outcomes. We highly recommend their services for any institution seeking advanced, ethical solutions in gene therapy research.
Related Services and Products
Creative Biolabs focuses on multiple parts of preclinical research. Wherever you are in the drug development timeline, choosing us will help you reduce the research risk and streamline your development. Please contact us in time for more information you desire to obtain.
Online Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NHP Biologicals from Creative Biolabs are for research, diagnostic, or manufacturing purposes only. They may not be intended for or are not approved for any other use.
Enter your email here to subscribe.
SubmitFollow us on
Copyright © 2024 Creative Biolabs. All rights reserved.